Opinion
Video
Safety Profile of Available Frontline Treatments LR-MDS
Author(s):
Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.
EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification
EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS
EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
EP: 4.Review of the COMMANDS Trial
EP: 5.Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice
EP: 7.Treatment Decision-Making Based on the COMMANDS Trials
EP: 8.Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
EP: 9.Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data
Now Viewing
EP: 10.Safety Profile of Available Frontline Treatments LR-MDS
EP: 11.1L treatment of lower-risk MDS beyond luspatercept
EP: 12.Sequencing Second-Line Treatments for LR-MDS
EP: 13.Perspectives of IMerge Study
EP: 14.Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
EP: 15.EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates
EP: 16.Final Thoughts on EHA 2024 Data for Lower-Risk MDS
- Briefly comment on the safety profile of available frontline treatments for patients with LR-MDS.
- How would you mitigate those events in your practice?
- How does toxicities observedimpact your overall treatment selection for patients?
Related Videos
Related Content
